Diplomat VP clinical services participates in HCV ‘think tank’
FLINT, Mich. — An executive from Diplomat Specialty Pharmacy recently participated in a program on hepatitis C therapy, the company said.
Diplomat said VP clinical services Gary Rice participated in the "think tank" program, "The New Paradigm of HCV Therapy – Integration of Oral Therapies into Best Practices," at the Harvard Medical School in Boston last week. The goal of the meeting was to provide a forum for exchanging the latest knowledge and opinions on the optimal diagnosis and management of people with chronic hepatitis C, with a focus on current and experimental therapies, access to therapy, diagnosis and testing, patient care management and patient advocacy.
"Diplomat Specialty Pharmacy strives to provide the best care, resources and current information to our patients," Rice said. "To have the opportunity to participate in this Harvard think tank and meet and discuss optimal hepatitis C treatments with some of the best medical minds in the country was a privilege and an invaluable return for our patients."
FDA approves Aciphex Sprinkle capsules
WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.
Eisai announced the approval of Aciphex Sprinkle (rabeprazole sodium) delayed-release capsules.
"We are proud to offer a new treatment option for young children who suffer from GERD," Eisai president and CEO Lonnel Coats said. "Eisai is committed to keeping the medical needs of patients and their families at the forefront of all that we do as part of our human healthcare corporate mission."
FDA approves injectable antihistamine using BD Simplist
FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved a drug administered through a new line of injection devices made by BD, the company said Wednesday.
BD announced the approval of diphenhydramine hydrochloride injection, an antihistamine, packaged in its recently launched Simplist pre-filled injectables, which are made by subsidiary BD Rx and designed to improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence and thus reduce the potential risk of medication errors.
"We have made a significant investment in [research and development] and manufacturing capabilities to build a state-of-the-art manufacturing facility that combines drug formulation with our manufacturing expertise," BD EVP and COO William Kozy said. "BD is well-positioned and uniquely suited to take this next step based on our demonstrated, 12-year history of continuous, reliable supply of our Flush products and existing leadership position in prefillable syringe manufacturing."
The company said that while traditional injections require up to 20 steps on the part of the physician, the Simplist requires about 12, in addition to featuring easy-to-read labels, bar-coding for easy identification and individually packaged, prefilled syringes.